Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
On Tuesday, Deutsche Bank (ETR:DBKGn) initiated coverage on Acadia Pharmaceuticals (NASDAQ:ACAD) with a Hold rating and a price target of $22.00. The firm’s analysts highlighted the arrival of a new CEO, Catherine Owen Adams, who is expected to provide a fresh vision for the company. Acadia Pharmaceuticals is recognized for its profitable base business, which includes two commercial-stage assets: Nuplazid for Parkinson’s disease psychosis (PDP), with loss of exclusivity (LOE) anticipated in 2029, and Daybue for Rett syndrome treatment. According to InvestingPro data, the company has demonstrated strong financial performance with impressive revenue growth of 47% in the last twelve months and maintains a healthy balance sheet with more cash than debt.
The analysts noted that while the company has a solid foundation, there are uncertainties regarding the long-term market penetration and persistency of Daybue. These uncertainties lead to a lower confidence in the fiscal year 2025 estimates and peak sales forecasts for Daybue, which are slightly below consensus. Deutsche Bank would need to observe a consistent quarter-over-quarter increase in net patient additions for Daybue to adopt a more constructive stance on Acadia Pharmaceuticals in the near term. InvestingPro analysis suggests the stock is currently trading near its Fair Value, with a strong financial health score of 3.65 (rated as "GREAT"). Subscribers can access 7 additional ProTips and comprehensive valuation metrics in the Pro Research Report.
The report suggests that Acadia’s stock is likely to remain rangebound over the next 12 months. This prediction is based on the expectation that significant catalysts for the stock will not occur until the release of Phase 3 data for ACP-101 in Prader-Willi syndrome (PWS) in the first half of 2026, and Phase 2 data for ACP-204 in Alzheimer’s disease psychosis (ADP) in mid-2026. These milestones have the potential to materially impact the company’s share value.
The analysts concluded that until these data are available, investors might not see substantial movement in the company’s stock. The initiation of coverage with a Hold rating reflects a cautious but watchful approach, as the market awaits the outcomes of Acadia’s ongoing clinical trials and the company’s ability to increase the adoption of Daybue.
In other recent news, Acadia Pharmaceuticals Inc. has been making significant strides in its operations. The company has submitted a Marketing Authorization Application to the European Medicines Agency for trofinetide, a potential therapy for Rett syndrome. This application follows positive outcomes from the Phase 3 LAVENDER study, suggesting significant improvements in patient conditions.
Simultaneously, Acadia has completed a $150 million asset sale of a Rare Pediatric Disease Priority Review Voucher, a significant financial transaction that will be detailed in the company’s upcoming annual report. In a separate development, Acadia has entered into an exclusive worldwide licensing agreement with Saniona for the development and commercialization of SAN711, a novel treatment for essential tremor.
Moreover, Acadia’s shares have reiterated an Outperform rating by Baird, primarily due to the recent in-licensing of SAN711. Lastly, the company has announced an executive shakeup with the departure of Brendan Teehan, its Executive Vice President, Chief Operating Officer, and Head of Commercial. These are the recent developments that have been taking place within Acadia Pharmaceuticals Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.